The bill S.106 aims to extend the tenure of the Psychedelic Therapy Advisory Working Group, which was originally established by Act and Resolves No. 126 in 2024. The Working Group is tasked with reviewing research on the cost-benefit profile of psychedelics for mental health improvement and making recommendations regarding a state program for healthcare providers to administer psychedelics in therapeutic settings. The bill proposes to expand the membership of the Working Group to include additional experts and stakeholders, thereby enhancing its capacity to monitor evolving research and programs related to psychedelic therapies in Vermont.

Key provisions of the bill include the establishment of new membership roles, such as an expert in psychedelic treatment from a Vermont hospital and a mental health professional with specialized training in psychedelic medicine. The Working Group will continue to review the latest research, monitor laws in other states, and propose a pilot project for psilocybin-assisted therapies for individuals with serious illnesses. The bill also outlines the requirement for the Working Group to submit a report with findings and recommendations by November 15, 2025, and specifies that the group will cease to exist on January 1, 2026. The act is set to take effect upon passage.